ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

TrialWire Platform AI Voice Screen to Boost Patient Engagement by 30% - Launched at Biotech Showcase 2025

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- TrialWire, a leader in clinical trial recruitment innovation, launched its groundbreaking AI Voice Screen service as part of the TrialWire Recruitment Platform powered by Salesforce Health Cloud, during the recent Biotech Showcase event in San Francisco.

Designed to capture an estimated 30% of potential patients who are missing due to screening communication challenges, the AI Voice Screen sets a new benchmark in managing medical literacy, language, and engagement.

For example, more than 50% of people don’t know the names of the medications they are on, and another 20% only know them by the size, color, and shape of tablets. The AI Voice Screener can wait while they check their scripts or even use image recognition.

This state-of-the-art solution uses advanced AI language models to streamline and optimize patient engagement and screening processes for clinical trials.

Key Features of the TrialWire AI Voice Screen Service:

  • Across all Languages and Medical Literacy:
    The AI-powered voice screening tool works across all languages and accommodates all medical literacy levels, improving screen success and ultimately bringing more people of diverse backgrounds, including age and demographics, into trials.
  • Enhanced Patient Engagement:
    The AI-powered voice screening tool facilitates personalized and real-time interactions with potential clinical trial participants. By leveraging natural language processing, the system accurately captures patient information and eligibility details, ensuring a seamless and efficient initial screening process.
  • Efficiency and Accuracy:
    This innovation not only accelerates the recruitment process but also minimizes screen fail rates and improves the accuracy of data collection for sites.
  • Scalability and Integration:
    TrialWire’s solution integrates effortlessly with the TrialWire Platform. Its scalable design accommodates clinical trials of any size, from early-phase studies to large-scale global trials, ensuring broad applicability across the industry.
  • Data Security and Compliance:
    Recognizing the importance of data privacy and security, the AI Voice Screen service adheres to strict regulatory standards, including HIPAA and GDPR compliance. TrialWire is committed to protecting patient information while delivering cutting-edge technology.

“The launch of our AI Voice Screen service represents a real step forward for clinical trial recruitment,” said Susan Fitzpatrick-Napier Founder and CEO at TrialWire.

“By leveraging advanced AI technologies, we are streamlining the screening process by creating a more engaging and accessible experience for patients.

“We were honored to be invited to present this innovation at Biotech Showcase and look forward to its positive impact on clinical trial efficiency and patient outcomes.”

About TrialWire:
TrialWire is at the forefront of digital innovation in clinical trial recruitment and management. Committed to improving patient access and engagement in clinical research, TrialWire combines cutting-edge technology with industry expertise to deliver solutions that enhance efficiency, data quality, and overall patient experience. For more information about the TrialWire Platform and its suite of services, visit Trial-Wire.com.

About Biotech Showcase:
Biotech Showcase is a premier event that brings together investors, innovators, and thought leaders in the biotechnology sector. The event serves as a platform for showcasing the latest breakthroughs, fostering collaborations, and driving the future of healthcare innovation.


Media Contact:
For interviews and more information:
Kate Jackson
TrialWire
team@trial-wire.com

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.